<DOC>
	<DOCNO>NCT01016912</DOCNO>
	<brief_summary>The purpose study identify least 1 dose daclatasvir safe , well tolerate , efficacious combine peginterferon-alfa ribavirin treatment hepatitis C virus genotype 1 chronically infected patient treatment-naïve nonresponsive standard care</brief_summary>
	<brief_title>Safety Efficacy Daclatasvir ( BMS-790052 ) Plus Standard Care ( Pegylated-interferon Alpha-2b Ribavirin ) Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Key Patients chronically infect hepatitis C virus ( HCV ) genotype 1 HCV RNA viral load ≥10*5* IU/mL screen Naïve nonresponsive current standard care Key Cirrhosis Hepatocellular carcinoma Coinfection hepatitis B virus , HIV1 HIV2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>